PROTEIN A RESIN MARKET ANALYSIS

Protein A Resin Market Size and Trends

The Global Protein A Resin Market is estimated to be valued at USD 1.50 Bn in 2024 and is expected to reach USD 2.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.

To learn more about this report, request sample copy

The market is expected to witness positive growth over the forecast period. Growing biopharmaceutical industry and increasing research and development activities in pharma and biotech companies are expected to drive the demand for protein A resins. Additionally, the increasing production of monoclonal antibodies for therapeutic applications will also contribute to the growth of the protein A resin market. Furthermore, the growing prevalence of chronic diseases globally is increasing the demand for biologic drugs, which, in turn, is propelling the market growth. However, availability of alternative affinity chromatography resins may hinder the market growth of protein A resin to a certain extent during the forecast period.

Increasing focus on developing biologics such as monoclonal antibodies (mAbs) for therapeutic purposes

The demand for monoclonal antibody therapies is increasing rapidly owing to their high specificity and ability to treat various chronic and life-threatening diseases. Protein A resin plays a critical role in the downstream purification process of monoclonal antibodies during their production. As the development and approval of novel monoclonal antibodies continue to grow for indications like cancer, autoimmune disorders, and infectious diseases, the requirement for protein A resin is expected to rise substantially. Major pharmaceutical companies are making heavy investments in developing highly innovative monoclonal antibody drugs and bringing them into the market. This massive pipeline of monoclonal antibodies in clinical trials and extensive research on complex antibody therapeutics will drive the need for large volumes of protein A resins over the coming years. For instance, in March 2024, ClinicalTrial.gov reported 1,248 ongoing clinical studies focused on monoclonal antibodies in the U.S. This significant number underscores a robust biopharmaceutical development pipeline centered around monoclonal antibodies. Consequently, the increasing demand for protein A resins is closely aligned with scaling purification and production processes, thereby driving the market growth in this sector.

Growth of Biosimilars Industry

The commercialization of many blockbusters biologic drugs is expected to lose patent protection in the upcoming years, opening vast opportunities for biosimilar products. Several pharmaceutical vendors are entering the biosimilars space and are engaged in the development of low-cost versions of popular biologics like monoclonal antibodies, hormones, cytokines, and clotting factors. Since protein A resin demonstrates high affinity and specificity for immunoglobulin G (IgG) molecules, it serves as an imperative technology in the downstream purification step of biosimilar manufacturing processes. The increasing biosimilars approvals and expanding global biosimilars market size will propel the demand for protein A resins from biosimilar companies. Many leading players are also focusing on enhancing protein A resin capabilities to fast-track the production of biosimilars. This is anticipated to substantially augment the growth of the protein A resin market in the foreseeable future.